MRES:
M2Enviro Expands R&D Efforts to Explore Diverse Classes of
Mycelium Composite Materials for Commercialization
CAPE TOWN, SOUTH AFRICA
-- June 14, 2023 -- InvestorsHub NewsWire -- Institute of
Biomedical Research Corp. (OTC
PINK: MRES)
("Institute of Biomedical Research" or the "Company"), a
nutraceutical biotechnology company focused on alternative
plant-based cannabinoids, medical psilocybin and mental health
therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, is pleased to
share the following update:
The sustainability
division of M2Bio Sciences, M2Enviro, is delighted to announce its
ongoing commitment to pushing the boundaries of sustainable
packaging with the development of its ground-breaking product,
Hempcelium™. This biodegradable and eco-friendly packaging
solution, made from hemp and mycelium, has gained significant
public interest throughout the R&D process due to its positive
environmental impact and the growing demand for sustainable
alternatives to single-use plastics. Furthermore, M2Enviro is
looking to open more R&D pipelines to explore different classes
of mycelium composite materials and their applications.
The packaging industry is
facing a critical need for sustainable solutions in response to the
rising demand for environmentally friendly packaging and growing
consumer awareness of the detrimental effects of single-use
plastics. Despite this demand, the industry still heavily relies on
non-biodegradable materials. It is imperative to find innovative
and eco-conscious alternatives that can meet the changing
requirements of businesses and consumers. M2Enviro acknowledges
this urgent challenge and is committed to greatly expanding its
research and development initiatives to explore novel types of
mycelium composite materials for the development of sustainable
packaging solutions.
One such example of a new
R&D pipeline is that of heat-pressed mycelium composite
materials. Subjecting mycelium composite materials to heat and
pressure increases the density of the material and changes the
orientation of the fibers in the material into the same plane. The
resulting material generally exhibits significantly higher
mechanical strength and durability than non-heat-pressed mycelium
composite materials that are just dehydrated. Applications for such
a material range from furniture, interior design applications, or
building materials.
"We are very proud
of Aidan and the M2Enviro team. In such a short period, they have
engineered a smart composite material that is ready for prime time.
The addressable market is massive, and we look forward to capturing
our fair share. Out with plastics and in with Hempcelium™"
- said Jeff Robinson,
Institute of Biomedical Research CEO.
Aidan Price, Managing
Director of M2Enviro, emphasizes the importance of M2Enviro's
mission, stating, "Our goal at
M2Enviro is to revolutionize the packaging and material industry by
providing innovative solutions that address the environmental
challenges we face today. Hempcelium™ is just the beginning of our
journey. We believe that by exploring different classes of mycelium
composite materials, we can unlock new opportunities and
applications that will further contribute to a greener
future."
In addition,
M2Enviro is pleased to
announce it will be launching a Pilot Project to test the
capabilities of Hemp in soil remediation. Soil remediation is the
process of restoring contaminated or degraded soil to a healthier
and more productive state. Hemp can absorb and accumulate high
levels of heavy metals, pesticides, solvents, and other pollutants
from the soil. The roots of hemp plants can reach deep into the
soil, secreting enzymes that aid in breaking down and converting
contaminants into less toxic forms. Furthermore, hemp is also
effective at atmospheric carbon sequestration. It can absorb carbon
dioxide from the atmosphere, converting and storing it as organic
carbon, to aid in the fight against climate change by offsetting
greenhouse gas emissions. This, in combination with its rapid
growth rate and ability for high biomass production, makes it a
strong candidate for use in biotechnological applications such as
biomaterials. M2Enviro is using hemp in our biodegradable and
sustainable Hempcelium™
packaging solution, an
alternative to petroleum-derived packaging products. M2Enviro's
Hempcelium™
is a product engineered
for the future and a circular economy.
M2Enviro's commitment to
sustainability and its innovative approach to mycelium composite
materials are poised to reshape the packaging and material
landscape. By continuously pushing the boundaries of research and
development, M2Enviro remains at the forefront of creating
environmentally friendly alternatives that meet the growing demands
of a conscious consumer base.
About
Institute of Biomedical Research Corp./ DBA M2Bio
Sciences
Institute of Biomedical
Research Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company
(OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333
2148
Find
M2Bio™ on social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe Harbour Statement -
In addition to historical information, this press release may
contain statements that constitute forward-looking statements
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements contained
in this press release include the intent, belief, or expectations
of the Company and members of its management team with respect to
the Company's future business operations and the assumptions upon
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance, involve risks and uncertainties
and that actual results may differ materially from those
contemplated by such forward-looking statements. Factors that could
cause these differences to include, but are not limited to, failure
to complete anticipated sales under negotiations, lack of revenue
growth, client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements.
